Earnings Call Insights: CareTrust REIT (CTRE) Q1 2026 Management View CEO David Sedgwick framed Q1 as momentum-driven external growth, saying, “We closed approximately $245 million of investments in the first quarter,” and added that “since the start of April, we have closed a dozen separate transactions for approximately $865 million,” including “our second SHOP investment.” Sedgwick linked portf...
Earnings Call Insights: CareTrust REIT (CTRE) Q1 2026 Management View CEO David Sedgwick framed Q1 as momentum-driven external growth, saying, “We closed approximately $245 million of investments in the first quarter,” and added that “since the start of April, we have closed a dozen separate transactions for approximately $865 million,” including “our second SHOP investment.” Sedgwick linked portfolio quality and tenant health to rent reliability, stating, “Our overall EBITDA rent coverage in our stabilized triple net portfolio remains very strong at 2.25x and EBITDARM coverage at 2.79x with broad-based improvements throughout the portfolio,” and “We collected 100% of contractual rent and interest in the first quarter.” Sedgwick highlighted shareholder and balance sheet milestones, saying results included “year-over-year FFO per share growth of 14%, a 16.4% increase to the dividend, an upgrade to investment grade by Moody’s and a raise to our FFO per share guidance for the year.” CFO Derek Bunker emphasized earnings growth and liquidity, saying, “Normalized FFO increased 38% over the prior year quarter to $107.4 million and normalized FAD increased 33% to $107.6 million,” and added, “We continue to have no scheduled debt maturities prior to 2028.” Outlook CFO Derek Bunker updated full-year targets: “We raised our 2026 full year guidance, projecting full year normalized FFO per share of $2 to $2.04 and normalized FAD per share of $1.98 to $2.02.” Bunker described the key framework behind the raised outlook, noting the updated guidance “includes the following key assumptions,” including “no new investments, loans or dispositions beyond those made year-to-date,” “no new debt or equity issuances beyond those made year-to-date,” “2.5% inflation-based rent escalators,” “$145 million of loans to be fully repaid throughout the remainder of the year,” and “no material change in the sterling to dollar spot exchange rate.” Compared with the prior quarter, the company’s guidanc...
Investing.com -- Wall Street has risen to new record highs on Friday, bouncing back from losses in the prior session, boosted by a jump in chip stocks and a stronger-than-expected April U.S. jobs report.
Investing.com -- Wall Street has risen to new record highs on Friday, bouncing back from losses in the prior session, boosted by a jump in chip stocks and a stronger-than-expected April U.S. jobs report.
Earnings Call Insights: Codexis (CDXS) Q1 2026 Management view Dr. Alison Moore said the company “accomplished a lot” since the prior call and plans to present “important new data on our ECO Synthesis technology” at the TIDES Conference, positioning ECO Synthesis as an enzymatic manufacturing platform for siRNA as pipelines broaden and scale constraints emerge. Dr. Moore highlighted a new ECO Synt...
Earnings Call Insights: Codexis (CDXS) Q1 2026 Management view Dr. Alison Moore said the company “accomplished a lot” since the prior call and plans to present “important new data on our ECO Synthesis technology” at the TIDES Conference, positioning ECO Synthesis as an enzymatic manufacturing platform for siRNA as pipelines broaden and scale constraints emerge. Dr. Moore highlighted a new ECO Synthesis capability: “the ability to generate siRNA with specific stereochemical control,” adding that Codexis’ enzymes can deliver “specific stereoisomer configurations,” which she said “have the potential to deliver improved potency,” while the company continues to study biological impact. Dr. Moore reiterated the role of the legacy business in funding ECO Synthesis investment, saying the small molecule biocatalysis business “remains an important part of Codexis,” and noting the portfolio “continues to grow with the recent approval of islatravir” in an HIV combination, with Codexis “supplying enzymes for this commercial product.” Britton Jimenez (Senior Vice President of Sales & Marketing) said Codexis has “over 50 opportunities in our sales pipeline with 40 individual companies demonstrating strong continued interest,” and added that “valuation work with our CDMO partners is progressing and long-term commercial discussions are also moving forward.” Georgia Erbez (CFO & Chief Business Officer) reported: “Total revenues were $15.2 million for the first quarter of 2026,” and said the increase was “primarily due to revenue from the Merck technology transfer agreement executed in the fourth quarter of 2025, which has now been fully recognized.” Outlook Georgia Erbez (CFO & Chief Business Officer) reiterated: “We reiterate our revenue guidance and expect 2026 revenue in the range of $72 million to $76 million,” and added, “we expect 2026 revenue to be more heavily weighted towards the second half of 2026 versus the first half.” Dr. Moore framed 2026 commercialization milestones a...
Earnings Call Insights: PubMatic (PUBM) Q1 2026 Management view "We delivered an exceptional first quarter with revenue and adjusted EBITDA ahead of guidance," said (Co-Founder, CEO & Director Rajeev Goel), adding that "emerging revenues grew over 80% year-over-year and climbed to 14% of total revenues, aided by AgenticOS." Goel tied the company’s strategy to a shift toward "AI-driven agentic adve...
Earnings Call Insights: PubMatic (PUBM) Q1 2026 Management view "We delivered an exceptional first quarter with revenue and adjusted EBITDA ahead of guidance," said (Co-Founder, CEO & Director Rajeev Goel), adding that "emerging revenues grew over 80% year-over-year and climbed to 14% of total revenues, aided by AgenticOS." Goel tied the company’s strategy to a shift toward "AI-driven agentic advertising" and said the summer 2025 strategy is "diversifying our DSP mix, growing in high consumer engagement channels such as CTV and mobile app and creating more value for key stakeholders." He also highlighted partnerships and integrations, including Amazon’s Dynamic Traffic Engine "now launched globally" and said early results showed "up to a 10% increase in CPM since its launch." "We delivered a strong quarter with Q1 revenue of $62.6 million and adjusted EBITDA of $2.6 million," said (Chief Financial Officer Steven Pantelick). "We also generated $10.7 million of free cash flow, a 17% free cash flow margin and returned value to shareholders through the repurchase of 1 million Class A common shares." Pantelick emphasized infrastructure and efficiency, stating the platform "efficiently process[es] over 1 trillion impressions per day," and said the company will "continue shifting our investment away from predominant capacity expansion towards targeted GPU-centric infrastructure" supporting CTV, mobile app, live sports and AgenticOS. Outlook Pantelick said PubMatic "expect[s] Q2 revenue to be in the range of $68 million to $70 million" and "Q2 adjusted EBITDA is expected to be in the range of $8 million to $10 million" while assuming "a similar FX headwind as Q1." On the legacy DSP headwind, Pantelick reiterated that Q2 "includes the impact from the legacy DSP" and that "Beginning in Q3, we expect to return to revenue growth and accelerate through the second half," with "margin expansion supported by targeted investments in sales and AI products, expense discipline and cont...
Reform makes gains in Labour’s working-class heartlands while Greens chip away at party’s progressive base Keir Starmer hates to lose. Unsurprisingly, he refused to walk away and end his premiership as Labour’s local election losses began to trickle in on Friday morning. Upon entering Downing Street in July 2024 after leading Labour to a historic general election victory, Starmer promised the publ...
Reform makes gains in Labour’s working-class heartlands while Greens chip away at party’s progressive base Keir Starmer hates to lose. Unsurprisingly, he refused to walk away and end his premiership as Labour’s local election losses began to trickle in on Friday morning. Upon entering Downing Street in July 2024 after leading Labour to a historic general election victory, Starmer promised the public that his government would “fight every day until you believe again”. Now, Starmer is faced with the uncomfortable truth that the frustrated yet united coalition that brought him into No 10 hoping for change is completely fractured and its discontent cannot be dismissed as early midterm blues. Continue reading...
Taiwan Semiconductor April Sales Grow At Slowest Pace In 6 Months Taiwan Semiconductor, world's largest dedicated independent semiconductor foundry, posted its slowest pace of monthly revenue expansion since October, highlighting the challenges of sustaining torrid AI-fueled pace of growth. Sales in April rose 17.5% to NT$410.7 billion ($13.1 billion), their smallest rise in about six months. Whil...
Taiwan Semiconductor April Sales Grow At Slowest Pace In 6 Months Taiwan Semiconductor, world's largest dedicated independent semiconductor foundry, posted its slowest pace of monthly revenue expansion since October, highlighting the challenges of sustaining torrid AI-fueled pace of growth. Sales in April rose 17.5% to NT$410.7 billion ($13.1 billion), their smallest rise in about six months. While the rise reflects just 30 days of business and its revenue can fluctuate month-to-month, the drop was notable; analysts expect the company’s June-quarter revenue to grow almost twice as fast, or at about 35% which means that May and June sales will have to be gangbusters to compensate for April's slowness. Taiwan’s largest company has become an essential player in the global AI industry by making cutting-edge semiconductors for the likes of Nvidia and AMD. That’s as Alphabet, Amazon.com, Meta and Microsoft said they are setting aside $725 billion for AI this year, significantly more than previously anticipated. The question of where all this money will come from will be the next big hurdle for the market (we discussed it here "" Banks Are Choking": The AI Debt Bubble Has Started To Burst ".) Offsetting the huge AI orderbook are plateauing smartphone and consumer electronics sales, where soaring memory chip costs are forcing brands to hike prices leading to a big drop in demand. Economic uncertainty is also dampening consumer demand in many parts of the world. For its part, TSMC has remained bullish on global AI chip demand. In April, the company raised its full-year sales guidance and said its own capital spending should trend toward the upper end of an existing forecast range of as much as $56 billion, conveying confidence in the year’s economic outlook. Tyler Durden Fri, 05/08/2026 - 14:40
Isomorphic Labs , an AI-powered drug discovery company spun out of Alphabet Inc. ’s Google DeepMind, is in advanced discussions to raise more than $2 billion in a new round of funding, according to people familiar with the plan. Thrive Capital , the venture firm that led Isomorphic Labs’ first funding round last year, is set to lead the new financing, said the people, who spoke on condition of ano...
Isomorphic Labs , an AI-powered drug discovery company spun out of Alphabet Inc. ’s Google DeepMind, is in advanced discussions to raise more than $2 billion in a new round of funding, according to people familiar with the plan. Thrive Capital , the venture firm that led Isomorphic Labs’ first funding round last year, is set to lead the new financing, said the people, who spoke on condition of anonymity as the information is not public. Alphabet is also participating, one person said, though the round is not yet closed. Isomorphic Labs is one of a growing number of businesses attempting to apply advances in AI to speed up drug discoveries and cut the costs of such work, despite many failures from Silicon Valley to expand into health and life sciences. Google rival OpenAI, also backed by Thrive, recently introduced a new AI model meant to help accelerate drug discovery. Thrive and Isomorphic Labs declined to comment. Google did not immediately respond to a request for comment. The additional funding would mark another step in Alphabet’s longtime plan to turn its futuristic bets into standalone businesses. Waymo, Alphabet’s autonomous driving unit, raised $16 billion at a $126 billion valuation earlier this year. Isomorphic Labs plans to use the new capital for its drug design engine, as well as to expand the business globally, one of the people said. The London-based company, formed in 2021, spun out of DeepMind to explore commercial potential for AlphaFold, an AI program for predicting protein structures. DeepMind Chief Executive Officer Demis Hassabis also runs Isomorphic Labs, which has recruited heavily from its sister company. The drug discovery unit forged partnerships with pharmaceutical firms Johnson & Johnson and Eli Lilly & Co in 2024. The next year, it announced an agreement to expand its work with Novartis.
In this article RKLB Follow your favorite stocks CREATE FREE ACCOUNT Cheng Xin | Getty Images Rocket Lab 's stock blasted 30% to a record high after the space company topped first-quarter revenue estimates and announced its largest launch deal on record. The Long Beach, California-based company reported $136.7 million in revenue for its space systems business and $63.7 million for its launch segme...
In this article RKLB Follow your favorite stocks CREATE FREE ACCOUNT Cheng Xin | Getty Images Rocket Lab 's stock blasted 30% to a record high after the space company topped first-quarter revenue estimates and announced its largest launch deal on record. The Long Beach, California-based company reported $136.7 million in revenue for its space systems business and $63.7 million for its launch segment. That topped FactSet estimates of $132.1 million and $59 million, respectively. Rocket Lab's backlog more than doubled from a year ago to $2.2 billion. Guidance also surpassed Wall Street's estimates. The company anticipates revenue between $225 million and $240 million during the second quarter, compared to a $207.5 million from LSEG. Rocket Lab's stock has more than quadrupled over the last year, benefiting from skyrocketing demand for businesses tied to the space economy ahead of SpaceX 's hotly anticipated IPO later this year. Demand for space systems and satellites is also escalating as President Donald Trump pursues his ambitious Golden Dome project and NASA's crewed Artemis missions rev up. Read more CNBC tech news OpenAI trial: Mother of Musk's children says he offered Altman a Tesla board seat Paul Tudor Jones says U.S. is late to regulating AI: 'We should have already done it' CoreWeave revenue more than doubles in first quarter, topping estimates Datadog stock soars 31% on blockbuster earnings as AI winners emerge in software Rocket Lab said Thursday that it signed its largest contract ever with a confidential customer for its Neutron and Electron rockets through 2029, weeks after landing a $190 million deal for 20 hypersonic test flights. The company is also buying space robotics maker Motiv Space Systems . "The demand signal is clear," CEO Peter Beck said on an earnings call with analysts, calling the pace of new product releases from the company this year "relentless." The company is gearing up for the first launch of its Neutron rocket after a qualificatio...